Partnerships
Partnering to advance the next generation of therapies.
We welcome conversations with academic institutions, biotech companies, clinical investigators, and investors aligned with patient-focused, capital-efficient development in oncology and metabolic diseases.
Why Partner With Us
Defined work. Shared milestones. Aligned incentives.
Our collaboration structures are built around defined work, shared milestones, and aligned incentives — not large upfront costs. We pair non-dilutive funding opportunities with strategic private investment to stretch every dollar and reduce risk for patients, partners, and investors.
TPP-Led from Day One
Every program begins with a Target Product Profile that defines success. Partners know exactly what we are building, for whom, and what it must show to advance.
Capital-Efficient Model
A lean parent-and-subsidiary structure keeps overhead low and resources focused on the programs. We leverage non-dilutive funding alongside strategic investment.
Milestone-Driven Governance
Clear go/no-go gates guide every development decision. Capital and effort are committed only when the data support the next step — protecting partners and investors alike.
Commercially Minded
We plan regulatory, clinical, and market strategy from Day One. Our team brings end-to-end experience from discovery through IND, clinical studies, and global approval.
Partnership Models
We work with partners across the development ecosystem.
01Academic & Research Institutions
We partner with universities and research institutions seeking a development and commercialization partner for promising discoveries. We provide the development expertise, regulatory strategy, and capital access to move strong science forward.
02Clinical Investigators
We work with clinical investigators interested in collaborative and investigator-sponsored studies. Our team provides regulatory guidance, study design support, and operational expertise to advance proof-of-concept work efficiently.
03Biotech Companies
We collaborate with biotech companies interested in co-development or out-licensing structures. Our lean model and milestone-driven approach make us a practical partner for programs that need a clear, capital-efficient development path.
04Investors & Foundations
We welcome conversations with investors, foundations, and family offices aligned with patient-focused, capital-efficient development in oncology and metabolic diseases. We pair non-dilutive funding with strategic investment to maximize impact.
How We Engage
A straightforward path from conversation to collaboration.
Initial Conversation
We start with an open conversation to understand your program, interest, or opportunity and share how we work.
Scientific Review
We conduct a rigorous scientific and strategic evaluation against our Target Product Profile criteria and development priorities.
Structure the Collaboration
We define the work, milestones, and incentives together — building a structure that aligns interests and keeps resources focused on the program.
Advance the Program
We execute with discipline, bringing in the right specialists at the right time and committing capital only when the data support the next step.
Get in Touch
Start a conversation.
Tell us about your program, institution, or interest. We review every inquiry and respond to those that align with our development priorities.